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Objectives. The purpose of this study was to estimate the effect 
of disopyramide on left ventricular diastolic function in patients 
with hypertrophic obstructive cardiomyopathy. 
Background. Although disopyramide has been reported to 
lessen clinical symptoms inpatients with hypertrophic obstructive 
cardiomyopathy, few data exist regarding its effect on diastolic 
function in these patients. 
Methods. Thirteen patients with hypertrophic cardiomyopathy 
(six with and seven without left ventricular outflow obstruction) 
were examined. Before and after intravenous disopyramide, he- 
modynamic and angiographic studies were performed. 
Results. In patients with outflow obstruction, pressure gradient 
at the outflow tract decreased from a mean -+ SD of 100 _+ 45 to 
26 ~- 33 mm Hg (p < 0.01). Although systolic function was similarly 
impaired in both groups, the time constant of left ventricular 
pressure decay (7) shortened from 56 -+ 10 to 44 _+ 8 ms (p < 0.01 )
and the constant of left ventricular chamber stiffness (kc) de- 
creased from 0.049 -+ 0.017 to 0.038 -+ 0.014 m2/ml (p < 0.01) only 
in patients with outflow obstruction. Shortening in ~" correlated 
best with decrease in left ventricular systolic pressure (r = 0.84, 
p < 0.01). In contrast, • was prolonged from 52 -+ 10 to 64 -+ 
11 ms (p < 0.01) and kc was unchanged in patients without 
outflow obstruction. 
Conclusions. The primary effects of disopyramide on the hyper- 
trophied left ventricle were negative inotropic and negative lusi- 
tropic. However, left veutricular diastolic properties in patients 
with outflow obstruction were improved with a decrease inoutflow 
pressure gradient. Relief of clinical symptoms in hypertrophic 
obstructive cardiomyopathy with disopyramide might be due in 
part to improvement of diastolic function, which appears second- 
ary to the reduction in ventricular afterload. 
(J Am Coil Cardiol 1995;26:768-75) 
Since the original report by Brock (1) of the concept of a 
functional stenosis of the left ventricular outflow tract, many 
investigators (2) have focused on the pressure gradient at the 
outflow tract in hypertrophic obstructive cardiomyopathy. In- 
deed, patients with hypertrophic obstructive cardiomyopathy 
are more severely disabled and are more symptomatic han are 
those with hypertrophic nonobstructive cardiomyopathy (3). 
Thus, negative inotropic drugs capable of reducing the gradi- 
ent, such as beta-adrenergic blocking agents, have been studied 
in expectation of lessening clinical symptoms. Disopyramide, 
an antiarrhythmic drug with a negative inotropic effect, is 
reported (4-9) to be more effective than propranolol in 
decreasing the pressure gradient and lessening clinical symp- 
toms in patients with hypertrophic obstructive cardiomyopa- 
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thy. However, the mechanism of clinical improvement by 
disopyramide has not been defined. 
Previous investigators (3,10-12) have suggested that 
marked impairment of diastolic performance, commonly ob- 
served in patients with hypertrophic cardiomyopathy with and 
without outflow obstruction, should be the main cause of the 
clinical symptoms of those patients. It is thus expected that 
drugs capable of reducing diastolic abnormalities such as 
calcium channel blockers may relieve clinical symptoms in 
patients with hypertrophic nonobstructive and obstructive car- 
diomyopathy (3). Although disopyramide has a calcium antag- 
onistic effect (13,14), this induces ymptomatic improvement 
only in patients with hypertrophic obstructive cardiomyopathy, 
not in those with hypertrophic nonobstructive cardiomyopathy. 
In the present study, to elucidate the mechanism of clinical 
improvement in patients with hypertrophic obstructive car- 
diomyopathy b  disopyramide, we assessed and compared the 
effect of disopyramide on left ventricular systolic and diastolic 
function in patients with hypertrophic cardiomyopathy with 
and without outflow obstruction. 
Methods  
Patients. We studied 13 patients with hypertrophic 
cardiomyopathy--6 with and 7 without outflow obstruction. 
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Their condition was diagnosed by established clinical, hemo- 
dynamic and echocardiograpbic criteria (3,15). Right ventric- 
ular myocardial biopsy, performed at cardiac atheterization n 
all patients, revealed characteristic histologic features of hy- 
pertrophic ardiomyopathy in all (3). The group with outflow 
obstruction comprised three women and three men, aged 46 to 
66 years (mean _+ SD 55 + 8); the group without outflow 
obstruction comprised two women and five men, aged 39 to 66 
years (mean 53 +_ 8). All had sinus rhythm and none had 
glaucoma, urinary retention or renal dysfunction that pre- 
cluded disopyramide administration. Informed consent was 
obtained from all patients. 
Cardiac catheterization. All patients were studied uring 
right-sided and retrograde l ft-sided cardiac atheterization by 
the percutaneous Seldinger technique. Pulmonary capillary 
wedge pressure and cardiac output were measured with a 7F 
balloon-tipped thermodilution catheter (model 7Ell-EN HS, 
Marcom International, Inc.) lying in the pulmonary artery. A 
7F pigtail catheter with a pressure transducer adjacent to the 
catheter tip (Mikro-Tip, model SPC-474A, Millar Instruments 
Inc.) was used to measure left ventricular pressure. The 
transducer was calibrated in normal saline solution at -37°C 
before insertion into the arterial system. Thereafter, the cath- 
eter tip was advanced to the left ventricular cavity. The side 
lumen of this catheter was connected to a standard fluid-filled 
manometer system (1295C, Hewlett-Packard) positioned at 
the midchest level, and baseline was checked frequently. Aor- 
tic pressure was measured with a fluid-filled 7F catheter 
(SOFTIP, Schneider Inc.) in the aortic root. Thus, simulta- 
neous left ventricular and aortic root pressures could be 
recorded. Pulmonary capillary wedge pressure and aortic 
pressure were measured with the same fluid-filled manometer 
systems, referring to atmospheric pressure at the midchest 
level. All pressures were recorded on a strip chart (RMC 2000, 
NihonKohden, Tokyo, Japan) at a paper speed of 100 mm/s. 
Biplane left ventriculography was performed in right anterior 
oblique (30 ° ) and left anterior oblique (60 ° ) views with injec- 
tion of 28 ml of contrast medium (iopamidol, Schering AG 
Pharma, Berlin, Germany) at a rate of 7 ml/s through acentral 
port of the Mikro-Tip catheter. Images were recorded on 
Kodak CSF film at a framing rate of 60 frames/s. 
Study protocol. All negative inotropic agents uch as pro- 
pranolol, verapamil and disopyramide were withdrawn for at 
least 48 h before examination. After baseline hemodynamic 
measurements, left ventriculography was performed. Then, 
disopyramide, 50 mg or 100 rag, was administered intrave- 
nously at a rate of 10 rag/rain. Immediately after administra- 
tion, hemodynamic measurements were repeated and a blood 
sample was obtained to measure the plasma concentration f 
disopyramide. Left ventriculography was then performed 
again. 
Left ventricular volume and pressure analysis. Left ven- 
tricular end-diastolic and end-systolic volumes were obtained 
from left ventriculograms according to the area-length method 
(16), and ejection fraction was calculated. Mitral regurgitation 
was evaluated semiquantitatively by left ventriculography into 
four grades (17). Left ventricular end-diastolic pressure and 
peak systolic pressure were read directly from the pressure 
recordings. Peak values of the first derivative of left ventricular 
pressure (peak positive and negative dP/dt) were obtained by 
differentiating the pressure using an on-line computer system 
(RMC 2000, NihonKohden, Tokyo, Japan). For the assess- 
ment of left ventricular relaxation, the left ventricular pressure 
data from the time of peak negative dP/dt o the time when left 
ventricular pressure returned to the level of 5 mm Hg above 
the preceding end-diastolic pressure were fitted to a monoex- 
ponential model (18): 
P = Poe t/~ + Pb, 
where P is left ventricular pressure (ram Hg), t is time (ms), Pb 
is nonzero asymptote (mm Hg), Po is initial value of pressure 
(ram Hg) measured with respect o Pb, and ~- is the time 
constant of left ventrieular pressure decay (ms). We calculated 
~" by nonlinear curve fitting on an off-line computer (Macintosh 
Quadra 700, Apple Computer Inc.) and the averaged correla- 
tion coefficient of the curve fitting was 0.993. 
Frame by frame analysis was performed for determination 
of left ventricular diastolic pressure-volume relations (16). Left 
ventricular pressure curves were scanned by an image scanner 
(GT-6500, EPSON, Tokyo, Japan) at 300 dpi and digitized at 
2-ms intervals with the same off-line computer. Matching of 
the individual cineframe with the left ventricular pressure was 
carried out by a numerical code which appeared on both the 
cinefilm and the pressure recordings. For the assessment of left 
ventricular chamber stiffness, left ventricular diastolic pres- 
sure-volume curves from the left ventricular minimal pressure 
to the left ventricular end-diastolic pressure were fitted to an 
empiric exponential equation (19,20): 
p = be k~v, 
where P is left ventricular pressure (ram Hg), V is left ventricular 
volume (ml/m2), b is a curve-fitting parameter representing 
pressure intercept (ram Hg), and kc is a curve-fitting parame- 
ter representing constant of left ventricular chamber stiffness 
(m2/ml). In addition, mean left ventricular stiffness (dP/dV 
[ram Hg.m2/ml]) was calculated as follows (21): 
dP/dV = (LVEDP - LVMDP)/SV, 
where LVEDP is left ventricular end-diastolic pressure 
(ram Hg), LVMDP is left ventricular minimal pressure 
(ram Hg), and SV is angiographic stroke volume (ml/m2). 
Statistical analysis. Data are expressed as mean value + 
SD. Differences in the patients' age and serum concentration 
of disopyramide between the two groups were compared by 
Student t test with unpaired observation. The other data were 
analyzed by two-way repeated measures analysis of variance 
and then tested by least significant difference test. We consid- 
ered results significant at a p value < 0.05. 
770 MATSUBARA ET AL  JACC Vol. 26, No. 3 
EFFECT OF DISOPYRAMIDE IN CARDIOMYOPATHY September 1995:768-75 
Table 1. Effect of Disopyramide on Hemodynamic Variables in 13 Patients With Hypertrophic Cardiomyopathy 
Disopyramide 
HR PCWP LVSP LVEDP AOSP AODP PG 
Age Injected Serum (beats/rain) (mm Hg) (mm Hg) (nam Hg) (mm Hg) (mm Hg) (mm Hg) 
(yr)/ Dose Concentration 
Pt No. Gender (nag) (m~;ml) C D C D C D C D C D C D C D 
Patients Without Outflow Tract Obstruction 
1 50/M 50 2.8 47 50 10 12 119 126 11 15 119 125 65 67 None 
2 57/M 50 3.3 82 91 11 15 124 128 15 16 139 123 81 74 None 
3 39/M /00 5.0 63 76 4 6 1511 145 4 7 154 163 71 87 None 
4 5I/F lfl0 4.2 74 72 7 t3 148 132 11 19 145 143 5(1 66 None 
5 66/M 100 4.5 63 67 8 17 145 143 11 18 146 143 75 90 None 
6 52/M 100 4.2 52 55 8 Ill 128 122 I 1 14 122 118 65 70 None 
7 54/F 1110 3.8 79 82 17 31i 155 143 24 28 165 153 75 89 None 
Mean 53 4.0 ~,6 711 9 15 138 134 12 17 141 138 69 78 
SD 8 11.7 13 14 4 8 14 9 6 6 17 17 10 l l  








Patients With Outflow Tract Obstruction 
8 49/1: 50 3.1 70 65 14 13 162 136 27 18 102 113 68 64 60 23 
9 46/F 100 4.1 66 70 13 8 225 148 13 13 93 125 56 66 132 23 
l0 66/1= 100 3.~ 711 72 17 11 259 154 23 13 109 134 54 61 150 20 
11 50/M 100 4.7 62 66 15 9 163 118 15 14 114 117 58 71 49 1 
12 55/M 10(/ 5.2 62 65 11 7 185 119 14 6 116 117 64 68 69 2 
13 63/M 100 4.1 68 67 16 14 230 198 25 16 90 1(17 52 57 140 91 
Mean 55 4.1 66 68 14f Ill+ 2045 146 20$ 13+ 1045 119+ 59t 65+ 100 26 
SD 8 0.8 4 3 2 3 40 30 6 4 11 9 6 5 45 33 
p value < 0.05 < IL()5 < 0.01 < 0.0l < 0.01 < 0.05 < 0.01 
*Statistically significant difference be~'een control value (C) and value after div~pyramide (D). Cp < 11.05, ~:p < 0.01, for patients without versus with outflow tract 
obstruction. AODP = aortic diastolic pressure; AOSP = aortic systolic pressure: F = female: HR = heart rate; LVEDP = left ventricular end-diastolic pressure; LVSP = 
left ventficular systolic pressure; M = male: PCWP = pulmona~' capillary, wedge pressure: PG = pressure gradient at left ventricular outflow tract; Pt = patient. 
Results 
In three patients with hypertrophic cardiomyopathy (Pa- 
tients 1 and 2 without outflow obstruction and Patient 8 with 
outflow obstruction), disopyramide injection was terminated 
after delivery of 50 mg because of time constraints. In the other 
10 patients, 100 mg of disopyramide was injected. The serum 
concentration of disopyramide was in the therapeutic range in 
all 13 patients and showed no significant difference between 
patients with and without outflow obstruction (4.1 _+ 0.8 vs. 
4.0 ± 0.7/xg/ml, p = 0.70). No adverse effects attributable to 
disopyramide injection were seen. Although there were some 
differences in baseline hemodynamic variables between the 
two patient groups due to differences in the disease (Table 1), 
there were no substantial differences in indexes of ventricular 
function before disopyramide injection (Table 2). 
Changes in hemodynamic variables (Table 1). Pressure 
gradient at the left ventricular outflow tract measured at rest 
decreased with disopyramide administration in all patients 
with hypertrophic obstructive cardiomyopathy (from 100 + 45 
to 26 ± 33 mm Hg, p < 0.01, Fig. 1). This reduction in pressure 
gradient was accompanied by a decrease in left ventricular 
peak systolic pressure (from 204 ± 40 to 146 _+ 30 mm Hg, p < 
0.01), and an increase in aortic systolic pressure (from 
104 ± 11 to 119 ± 9 mm Hg, p < (I.01). In patients without 
outflow obstruction, aortic systolic pressure and left ventricular 
systolic pressure were unchanged, and only aortic diastolic 
pressure increased. Pulmonary capillary wedge pressure and 
left ventricular end-diastolic pressure in patients with outflow 
obstruction decreased from 14 ± 2 to 10 _+ 3 mm Hg (p < 0.05) 
and from 20 _+ 6 to 13 ± 4 mm Hg (p < 0.01), respectively. In
contrast, pulmonary capillary wedge pressure increased from 
Figure 1. Representative pressure recordings in a patient with hyper- 
trophic obstructive cardiomyopathy. Simultaneous left ventricular 
(LV) and aortic (AO) pressures before (control) and immediately after 
disopyramide (100 mg intravenously) administration. In this case, the 
pressure gradient decreased from 69 to 2 mm Hg. ECG = electrocar- 
diogram. 
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9 +_ 4 to 15 _+ 8 mm Hg (p < 0.01) and left ventricular 
end-diastolic pressure increased from 12 _+ 6 to 17 _+ 6 mm Hg 
(p < 0.01) in patients without outflow obstruction. Mitral 
regurgitation was detected in two patients without outflow 
obstruction and was unchanged by disopyramide administra- 
tion. Mitral regurgitation was detected in all six patients with 
outflow obstruction, and was decreased in all six by disopyra- 
mide administration (from 1.8 +_ 0.4 to 0.5 _+ 0.5, p < 0.01). 
Heart rate in both groups increased after disopyramide (p < 
0.05). 
Changes in ventricular function (Table 2). After adminis- 
tration of disopyramide, left ventricular end-diastolic and 
end-systolic volumes increased in both groups, resulting in a 
decrease of ejection fraction from 74 = 8% to 67 +_ 8% in 
patients with outflow obstruction (p < 0.01) and from 59 _+ 
13% to 49 ___ 16% (p < 0.01) in patients without outflow 
obstruction. Angiographic stroke volume decreased similarly 
in both groups, from 49 _ 16 to 46 + 16 ml/m 2 in patients 
with outflow obstruction (p < 0.05) and from 46 + 10 to 41 _+ 
11 ml/m 2 in patients without outflow obstruction (p < 0.05). 
Cardiac index measured by the thermodilution method tended 
to increase, from 3.1 _+ 0.3 to 3.4 + 0.6 liters/rain per m 2, in 
patients with outflow obstruction but decreased from 3.6 _+ 0.7 
to 3.0 +_ 0.5 liters/min per m 2 in patients without obstruction 
(p < 0.05). Peak positive dP/dt decreased similarly in both 
groups by disopyramide administration (from 1,732 _+ 321 to 
1,235 _+ 174 mm Hg/s, p < 0.01 in patients with outflow 
obstruction and from 1,984 +_ 387 to 1571 _+ 530 mm Hg/s, p < 
0.01, in patients without obstruction). Unlike changes in peak 
positive dP/dt, peak negative dP/dt decreased only in patients 
without outflow obstruction, from -1,898 _+ 513 to -1,514 _+ 
394 mm Hg/s (p < 0.01). Although ~" prolonged significantly in 
patients without outflow obstruction (from 52 _+ 10 to 64 _+ 
11 ms, p < 0.01), it was shortened in all patients with obstruction 
(from 56 _+ 10 to 44 _+ 8 ms, p < 0.0l) after disopyramide 
administration. The diastolic pressure-volume relation was shifted 
downward and rightward in all patients with outflow obstruc- 
tion. The constant kc decreased from 0.049 _+ 0.017 to 0.038 _+ 
0.014 m2/ml (p < 0.01), and mean left ventricular stiffness 
decreased from 0.26 _+ 0.09 to 0.20 +_ 0.08 mm Hg.m2/ml (p < 
0.01), (Fig. 2, top). In contrast, kc was unchanged, whereas mean 
left ventricular stiffness increased from 0.23 _+ 0.13 to 0.29 _+ 
0.13 mm Hg.m2/ml (p < 0.01) in patients without outflow 
obstruction. These results indicated that diastolic pressure- 
volume relation in patients without outflow obstruction was only 
shifted to the steeper portion on the substantially same curve (Fig. 
2, bottom). 
To define contributors to change of diastolic indexes, 
changes in ~- and kc were compared with changes in left ventric- 
ular pressure, aortic pressure and ventricular volume in all the 
cases pooled from both groups. Percent change in r showed 
best correlation with percent change in left ventricular systolic 
pressure (r = 0.84, y = 1.20x ~ 19.7, p = 0.003, SEE = 13.8%, 
Fig. 3). Change in kc was not simply correlated with changes in 
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Figure 2. Left ventricular (LV) diastolic pressure-volume r lation 
before (open circles) and after (solid circles) disopyramide injection in 
two patients with hypertrophic cardiomyopathy, Patient 13 (top) with 
outflow tract obstruction and Patient 7 without outflow obstruction 
(bottom). The diastolic pressure-volume relation is shifted downward 
and to the right by disopyramide in the patient with outflow obstruc- 
tion but is unchanged by disopyramide in the patient without obstruc- 
tion. 
Discussion 
Effect of disopyramide on systolic function. The primary 
action of disopyramide on cardiac myocytes has been consid- 
ered to be a sodium channel blocking effect. Disopyramide 
decreases intracellular sodium and slows down calcium influx 
through sodium-calcium exchange system, acting as a negative 
inotrope (13,14). A negative inotropic effect of disopyramide 
Figure 3. Relation between percent change in left ventricular peak 
systolic pressure (LVSP) and percent change in time constant of left 
ventricular relaxation (r) in the 13 study patients. The percent change 













/U  °° 
° o 
" ° I sPE2OQ3% 
i 
-~s 6 25 
% change in LVSP 
JACC Vol. 26, No. 3 MATSUBARA ET AL. 773 
Septernber 1995:768-75 EFFECT OF DISOPYRAMIDE IN CARDIOMYOPATHY 
has been well known clinically in several cardiac diseases 
(22,23), but only a few investigators (4,5) have demonstrated it 
in hypertrophic cardiomyopathy. Although ejection fraction is 
a common index of systolic function (20,23,24), it is not 
suitable for assessing the effect of disopyramide on systolic 
function in patients with hypertrophic cardiomyopathy with 
outflow obstruction because afterload conditions are remark- 
ably changed by disopyramide administration, asshown here 
(25). We demonstrated a negative inotropic effect of disopy- 
ramide in patients with hypertrophic cardiomyopathy with and 
without outflow obstruction ot only with a decrease of 
ejection fraction but also with a decrease in peak positive 
dP/dt. 
Two hydrodynamic forces cause systolic anterior motion of 
the mitral valve: the venturi force and the drag force (26-29). 
The negative inotropic effect of disopyramide would decrease 
both forces and decrease systolic rnitral valve anterior motion, 
resulting in a reduction of outflow pressure gradient (4-9). 
Effect of disopyramide on diastolic function. The lusitropic 
effect of disopyramide is less well understood than its inotropic 
effect. Disopyramide decreases the magnitude ofpeak positive 
and negative dP/dt and prolongs relaxation in the normal rat 
heart (30), but little is known about its effect on diastolic 
function in human hypertrophied left ventricle. Although Fifer 
et al. (31) reported that disopyramide did not affect left 
ventricular relaxation i  patients with hypertrophic cardiomy- 
opathy, their data were pooled from patients with and without 
outflow obstruction. Our results clearly demonstrated that the 
primary effects of disopyramide were negative inotropic and 
negative lusitropic in patients without outflow obstruction. 
However, in patients with outflow obstruction, disopyramide 
improved iastolic properties, whereas it caused eterioration 
of systolic properties. 
A previous report (5) attributed the decrease of left ven- 
tricular end-diastolic pressure in patients with outflow obstruc- 
tion after disopyramide to its primary calcium antagonistic 
effect, as with verapamil (20). However, the present results and 
previous experimental data (30) showing deteriorated relax- 
ation after disopyramide cannot be explained simply by the 
calcium antagonistic effects. 
Relaxation of the ventricle is governed by load, inactivation 
and nonuniform distribution of load and inactivation (32). A 
load applied in the first two thirds of systole (contraction load) 
delays the onset and the rate of ventricular relaxation, whereas 
a load applied in the last one third of systole results in the early 
onset of relaxation (32). Wigle et al. (3) suggested that left 
ventricular outflow obstruction in hypertrophic obstructive 
cardiomyopathy would act as a contraction load rather than as 
a late systolic load and would impair relaxation. Moreover, 
outflow obstruction should enhance the nonuniformity ofload, 
because the left ventricle is divided by the obstruction i to two 
chambers with different loads. Reduction of contraction load 
and regional nonuniformity by reducing the outflow obstruc- 
tion after disopyramide should overcome the influence of the 
primary negative lusitropic effect of disopyramide; thus, relax- 
ation improved only in patients with outflow obstruction. 
Correlation between a change in r and a change in left 
ventricular peak systolic pressure would support his hypothe- 
sis. 
Patients with outflow obstruction had a lower pulmonary 
capillary wedge pressure after disopyramide than did those 
without obstruction. Because ventricular filling load enhances 
relaxation (3,32), a decrease in pulmonary capillary wedge 
pressure may impede relaxation. Nevertheless, relaxation im- 
proved in patients with outflow obstruction, indicating a dra- 
matic effect of the relief of the obstruction. 
Left ventricular chamber stiffness constant is directly re- 
lated to myocardial stiffness and myocardial mass and inversely 
related to left ventricular chamber volume (3,19). In addition, 
the chamber stiffness constant could be influenced by a process 
of left ventricular elaxation (19). Myocardial stiffness and 
myocardial mass should not be changed by disopyramide 
administration, because these variables were determined by 
histologic abnormalities such as the amount of intercellular 
connective tissue or fibrosis (3). Therefore, we considered that 
the effect of increased chamber volume and the effect of 
delayed relaxation might be balanced in patients without 
outflow obstruction, resulting in an unaltered passive chamber 
stiffness constant after disopyramide administration. In pa- 
tients with outflow obstruction, the effects of both increased 
chamber volume and shortened (or more complete) relaxation 
caused by administration f disopyramide might help decrease 
the passive chamber stiffness constant. 
Thus, disopyramide may facilitate diastolic filling in patients 
with outflow obstruction (33) with an improvement in left 
ventricular diastolic properties. 
Effect on other hemodynamic variables. Cardiac output in 
patients with hypertrophic cardiomyopathy without outflow 
obstruction decreased with disopyramide administration, as 
similarly reported in normal or failing hearts (22,23). In 
contrast, cardiac output in patients with outflow obstruction 
tended to increase. This difference may be caused by changes 
in mitral regurgitant volume, because angiographic stroke 
volume in both groups was similarly decreased and heart rate 
in patients with outflow obstruction was almost unaltered by 
disopyramide administration. As described earlier, disopyra- 
mide should decrease systolic anterior movement of the mitral 
valve and regurgitant volume (5), resulting in an increase in 
forward output. A reduction in the outflow tract pressure 
gradient and in afterload should also contribute to a decrease 
in regurgitant volume and to an increase in forward output. 
Clinical implications. Others (4,6,7,9) have already re- 
ported that disopyramide can improve xercise tolerance and 
clinical symptoms in patients with hypertrophic obstructive 
cardiomyopathy. The present study confirmed that disopyra- 
mide improved left ventricular diastolic properties through 
afterload reduction i  patients with outflow obstruction. Relief 
of clinical symptoms in patients with outflow obstruction with 
disopyramide (4,6,7,9) might in part relate to these salutary 
effects on left ventricular diastolic function. 
There are several reasons why disopyramide is more useful 
than propranolol and verapamil n treating hypertrophic ob- 
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structive cardiomyopathy, although all three agents can de- 
crease outflow tract obstruction. First, only disopyramide can 
both decrease outflow tract obstruction and improve left 
ventricular diastolic properties in patients with outflow ob- 
struction. Hess et al. (20) reported that propranolol impaired 
left ventricular elaxation in patients with outflow obstruction. 
Verapamil improves relaxation but has no significant effect on 
passive diastolic properties (20). Second, disopyramide has 
been reported (5,6) to produce a more significant decrease in 
pressure gradient than that produced by propranolol or ve- 
rapamil. In addition, verapamil has the potential risk of 
worsening outflow tract obstruction as a result of peripheral 
vasodilation (34). Finally, disopyramide prevents atrial fibril- 
lation, which causes worsening of clinical symptoms in patients 
with outflow obstruction (3,5). Therefore, disopyramide may 
be a first choice for treating hypertrophic obstructive cardio- 
myopathy. 
Limitations of the study. Our study has several imitations. 
1) Because we wanted to obtain simultaneous measure- 
ments of left ventricular volume and pressure during ventricu- 
lography, we used not the dual but the single micromanometer- 
tipped catheter with a port for contrast injection. Therefore, 
we could not obtain simultaneous high fidelity pressure mea- 
surements of the left ventricle and the ascending aorta. 
2) Contrast medium can influence left ventricular function. 
However, because its influence would be similar for patients 
with hypertrophic ardiomyopathy with and without obstruc- 
tion, its use in our study should not have affected our results. 
3) We estimated the acute hemodynamic effects of intrave- 
nous disopyramide. Previous studies (4-9) demonstrated that 
oral and intravenous disopyramide have similar beneficial 
effects in patients with outflow obstruction. In the present 
study, the serum concentration of disopyramide was in the 
therapeutic range. Therefore, we could speculate that oral and 
intravenous disopyramide may have similar effects on left 
ventricular diastolic function in patients with outflow obstruc- 
tion. Other studies are required to demonstrate the long-term 
effect of oral disopyramide on left ventricular diastolic prop- 
erties. The long-term effects of disopyramide in such areas as 
prevention of sudden death or improvement of survival rate 
should be clarified. 
4) The number of patients studied was relatively small. 
However, our observations were quite consistent in all of our 
patients; that is, after disopyramide left ventricular diastolic 
properties improved in all patients with outflow obstruction 
and deteriorated in all patients without such obstruction. 
Therefore, our conclusions are unlikely to be altered by a 
larger study group. 
Conclusions. Although the pr ima l '  effects of disopyramide 
on the hypertrophic ventricle were negatively inotropic and 
lusitropic, disopyramide not only decreased outflow tract ob- 
struction but also improved left ventricular diastolic properties 
in our patients with outflow obstruction. These salutary effects 
on diastolic properties may be due to a reduction of afterload 
with disopyramide. 
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